Missing the Covid boat, Junshi stumbles back to old business
Despite developing an oral drug to treat Covid, the biotech company's revenue fell sharply and its net loss widened by nearly 40% in the first quarter Key Takeaways: Junshi Bioscience's…
Recent Articles
Missing the Covid boat, Junshi stumbles back to old business
1877.HK
688180.SHG
RELATED ARTICLES
-
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
1877.HK 688180.SHG -
Junshi hopes new scientist CEO can cure its woes
1877.HK 688180.SHG
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
HBM gets health boost from drug licensing deals
2142.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Everest reaches new heights on growing drug sales
1952.HK
